Verteporfin Suppresses YAP-Induced Glycolysis in Breast Cancer Cells

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):1–9. doi:10.3322/caac.21492.
   Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.19323.
   PubMed Web of Science ®Google Scholar
• Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120–1133. doi:10.1016/j.cell.2007.07.019.
   PubMed Web of Science ®Google Scholar
• Koo JH, Guan KL. Interplay between YAP/TAZ and Metabolism. Cell Metab. 2018;28(2):196–206. doi:10.1016/j.cmet.2018.07.010.
   PubMed Web of Science ®Google Scholar
• Ibar C, Irvine KD. Integration of hippo-YAP signaling with metabolism. Dev Cell. 2020;54(2):256–267. doi:10.1016/j.devcel.2020.06.025.
   PubMed Web of Science ®Google Scholar
• Yousefi H, Delavar MR, Piroozian F, et al. Hippo signaling pathway: a comprehensive gene expression profile analysis in breast cancer. Biomed Pharmacother. 2022;151:113144. doi:10.1016/j.biopha.2022.113144.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lin Z, Zhou Z, et al. Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP-TEAD protein-protein interaction. ACS Med Chem Lett. 2014;5(9):993–998. doi:10.1021/ml500160m.
   PubMed Web of Science ®Google Scholar
• Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–1971. doi:10.1101/gad.1664408.
   PubMed Web of Science ®Google Scholar
• Guimei M, Alrouh S, Saber-Ayad M, et al. Inhibition of yes-associated protein-1 (YAP1) enhances the response of invasive breast cancer cells to the standard therapy. Breast Cancer (Dove Med Press). 2020;12:189–199. doi:10.2147/bctt.S268926.
   PubMed Web of Science ®Google Scholar
• Gibault F, Corvaisier M, Bailly F, et al. Non-photoinduced biological properties of verteporfin. Curr Med Chem. 2016;23(11):1171–1184. doi:10.2174/0929867323666160316125048.
   PubMed Web of Science ®Google Scholar
• Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300–1305. doi:10.1101/gad.192856.112.
   PubMed Web of Science ®Google Scholar
• Lin C, Xu X. YAP1-TEAD1-Glut1 axis dictates the oncogenic phenotypes of breast cancer cells by modulating glycolysis. Biomed Pharmacother. 2017;95:789–794. doi:10.1016/j.biopha.2017.08.091.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.309.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10(9):671–684. doi:10.1038/nrd3504.
   PubMed Web of Science ®Google Scholar
• Ulaner GA. PET/CT for patients with breast cancer: where is the clinical impact? AJR Am J Roentgenol. 2019;213(2):254–265. doi:10.2214/ajr.19.21177.
   PubMed Web of Science ®Google Scholar
• Groheux D, Martineau A, Teixeira L, et al. (18)FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. Breast Cancer Res. 2017;19(1):3. doi:10.1186/s13058-016-0793-2.
   PubMedGoogle Scholar
• Jiang S, Zhang LF, Zhang HW, et al. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. Embo J. 2012;31(8):1985–1998. doi:10.1038/emboj.2012.45.
   PubMed Web of Science ®Google Scholar
• Zhang LF, Lou JT, Lu MH, et al. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma. Embo J. 2015;34(21):2671–2685. doi:10.15252/embj.201591803.
   PubMed Web of Science ®Google Scholar
• Bum-Erdene K, Yeh IJ, Gonzalez-Gutierrez G, et al. Small-molecule cyanamide pan-TEAD·YAP1 covalent antagonists. J Med Chem. 2023;66(1):266–284. doi:10.1021/acs.jmedchem.2c01189.
   PubMed Web of Science ®Google Scholar
• Si Y, Ji X, Cao X, et al. Src inhibits the hippo tumor suppressor pathway through tyrosine phosphorylation of Lats1. Cancer Res. 2017;77(18):4868–4880. doi:10.1158/0008-5472.Can-17-0391.
   PubMed Web of Science ®Google Scholar
• Palomo-Irigoyen M, Pérez-Andrés E, Iruarrizaga-Lejarreta M, et al. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. J Clin Invest. 2020;130(7):3848–3864. doi:10.1172/jci130379.
   PubMed Web of Science ®Google Scholar
• Misra JR, Irvine KD. The hippo signaling network and its biological functions. Annu Rev Genet. 2018;52(1):65–87. doi:10.1146/annurev-genet-120417-031621.
   PubMedGoogle Scholar
• Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163(4):811–828. doi:10.1016/j.cell.2015.10.044.
   PubMed Web of Science ®Google Scholar
• Clara JA, Monge C, Yang Y, et al. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020;17(4):204–232. doi:10.1038/s41571-019-0293-2.
   PubMed Web of Science ®Google Scholar
• Barrette AM, Ronk H, Joshi T, et al. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models. Neuro Oncol. 2022;24(5):694–707. doi:10.1093/neuonc/noab244.
   PubMed Web of Science ®Google Scholar
• Vigneswaran K, Boyd NH, Oh SY, et al. YAP/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma. Clin Cancer Res. 2021;27(5):1553–1569. doi:10.1158/1078-0432.Ccr-20-0018.
   PubMed Web of Science ®Google Scholar
• Dai M, Yan G, Wang N, et al. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy. Nat Commun. 2021;12(1):3055. doi:10.1038/s41467-021-23316-4.
   PubMed Web of Science ®Google Scholar
• Abdelmohsen K, Panda AC, Munk R, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017;14(3):361–369. doi:10.1080/15476286.2017.1279788.
   PubMed Web of Science ®Google Scholar
• Heinonen M, Fagerholm R, Aaltonen K, et al. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 2007;13(23):6959–6963. doi:10.1158/1078-0432.Ccr-07-1432.
   PubMed Web of Science ®Google Scholar
• Calses PC, Crawford JJ, Lill JR, et al. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer. 2019;5(5):297–307. doi:10.1016/j.trecan.2019.04.001.
   PubMed Web of Science ®Google Scholar
• Dey A, Varelas X, Guan KL. Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19(7):480–494. doi:10.1038/s41573-020-0070-z.
   PubMed Web of Science ®Google Scholar